在接受腹腔外科手术的肥胖个体中经过外科手术的外科手术时发生的腹肌溶解:目前的状况
Gilberto Duarte-Medrano1, Natalia Nuño-Lámbarri2,3, Marissa Minutti-Palacios1
1Anesthesiology Department, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico.
Healthcare (Basel, Switzerland)
|October 25, 2024
概括
肌肉损伤并发症,在减肥手术中的肌肉损伤并发症,往往是由组织压缩和不移动引起的. 早期诊断和补水是关键,但预防损伤仍然是一个挑战.
科学领域:
- 麻醉学 麻醉学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 手术并发症 手术并发症
背景情况:
- 轮骨髓溶解是减肥手术的一个严重并发症.
- 危险因素包括组织压缩和长时间的不运动,特别是在下肢,部和腰部地区.
- 临床症状包括肌肉疼痛,软弱和尿暗,血清肌酸激酶升高作为关键生物标志物.
研究的目的:
- 要突出诊断和管理腹腔外科手术患者的腹肌溶解的挑战.
- 强调预防和早期干预的重要性.
- 讨论目前预防损伤的管理策略和局限性.
主要方法:
- 审查关于腹部外科手术中的手术内拉布地质溶解现有文献.
- 对临床表现,诊断生物标志物和风险因素的分析.
- 讨论术后管理,包括水化和复苏方案.
主要成果:
- 组织压缩和长时间的固定是拉布多米解的主要危险因素.
- 血清肌酸激酶的升高是最可靠的诊断标志物.
- 用乳酸林格或0.9%盐水进行静脉内液体复苏对于管理水分是至关重要的.
结论:
- 术后诊断需要高临床怀疑在减肥患者.
- 在这个弱势群体中,预防至关重要.
- 早期开始治疗至关重要,尽管预防二次损伤仍然具有挑战性.
相关概念视频
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...


